Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
PUMA BIOTECHNOLOGY, INC.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-46.2% vs price
Base Case (Median)
-13.7% vs price
Bull Case (75th pct.)
22.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $2.42 | -73.9% | High (40%) |
| PE Comparable | $11.60 | 25.6% | Medium (25%) |
| Graham Number | $5.47 | -40.8% | Medium (40%) |
| EV/EBITDA | $10.47 | 13.3% | Medium (20%) |
| EV/FCF | $16.13 | 74.6% | Medium (20%) |
| Earnings Power Value | $4.80 | -48.0% | Medium (50%) |
Based on 6 out of 8 methods, PBYI appears fairly valued at the current price of $9.24. The base case fair value of $7.97 implies 13.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.
